Navigation Links
SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/3/2008

BOTHELL, Wash., Nov. 3 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (Amex: DDD) today announced that the Company will present at the Rodman & Renshaw 10th Annual Healthcare Conference to be held on November 10-12 at the New York Palace Hotel in New York City.

Daniel O. Wilds, SCOLR Pharma's President and CEO, is scheduled to present an overview of the Company's operations on Tuesday, November 11, 2008 at 12:00 p.m. ET. For more information please visit the conference website: http://www.rodm.com/conferences?id=19.

About SCOLR Pharma

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company. SCOLR Pharma's corporate objective is to combine its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platform is based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425.368.1050 or visit http://www.scolr.com/.

Contact:

Investor Relations:

Cameron Associates

Kevin McGrath

212.245.4577

Kevin@cameronassoc.com


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
3. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
4. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
5. China Biopharma, Inc. Announces New Plan of Operation
6. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
7. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
8. Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
9. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
10. Avicena Group to Present at Noble Financial Conference
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 22, 2017 , ... Seventy-one members ... named Fellows of the Society this year, the Fellows Committee has announced. The ... of optics, photonics, and imaging as well as their service to the Society ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Park ... free AFM Luncheon for all SPIE attendees and Park customers ... just one block from the San Jose Convention Center. The luncheon will feature ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... provider of women’s health, primary care, and specialty education, announced today it ... Education (ACCME). ACCME’s Accreditation with Commendation is a six-year accreditation and is ...
(Date:2/22/2017)... ... , ... LabRoots , the leading provider of educational and interactive virtual ... announce the launch of a new scholarship for young scientists seeking a degree in ... is open to all high school seniors, 17 years or older; as well as ...
Breaking Biology Technology:
(Date:1/24/2017)... 24, 2017 Biopharm Reports has carried ... use of nuclear magnetic resonance spectroscopy (NMR). This ... profiled current practices, developments, trends and end-user plans ... growth and opportunities. These areas include growth in ... needs and innovation requirements, hyphenated NMR techniques, main ...
(Date:1/21/2017)... 2017 Research and Markets has announced the ... report to their offering. ... The global voice recognition biometrics market to grow at ... The report covers the present scenario and the growth prospects of ... market size, the report considers the revenue generated from the sales ...
(Date:1/18/2017)... ROCKVILLE, Md. , Jan. 18, 2017  In ... with respect to mergers and acquisitions (M&A), and Kalorama ... reasons for such acquisitions have been shifting. Generally, uncertainty ... and the U.S. has changed the acquisitions ... situation has resulted in companies buying partners outside of ...
Breaking Biology News(10 mins):